Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases

May 13, 2023

https://www.globenewswire.com/news-release/2023/05/12/2668190/0/en/Aligos-Therapeutics-Announces-Research-Collaboration-and-Development-Agreement-with-Xiamen-Amoytop-Biotech-Co-Ltd-for-Use-of-Aligos-Oligonucleotide-Platform-for-the-Treatment-of-Li.html

SOUTH SAN FRANCISCO, Calif., May 12, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq:ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. Ltd. (“Amoytop”) for the use of Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.

Read more at globenewswire.com

Related news for (ALGS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.